Strontium ranelate is a dual action bone agent (DABA). It inhibits bone resorption and stimulates bone formation, inhibiting osteoclast differentiation while activating gene expression in osteoblasts. While its exact mechanism of action is unknown, one hypothesis is that both anabolic and anti-catabolic activities may involve antagonizing nuclear factor-KB (NF-KB) activation in bone cells. Strontium ranelate has been shown to inhibit the receptor activator of NF-KB ligand (RANKL)-induced nuclear translocation of NF-KB and activator protein-1. Strontium ranelate has been used clinically for the treatment of osteoporosis and a recent multinational study indicates the drug can also be used to treat osteoarthritis.
Strontium ranelate is a dual action bone agent (DABA); inhibitor of bone resorption and stimulator of bone formation.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.